Our Story
A new approach to drug discovery
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets.
By leveraging the company’s ExoSight™ platform, we are developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, our team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Expanding our druggable universe
While there are roughly 10,000 proteins involved in human disease, only ~700 are currently accessible to the pharmaceutical industry as targets for new drug development. Exo aims to expand the druggable universe with exosites which enable a new way to target and reprogram enzymes.
Built on foundational academic insights
Exo’s scientific approach is based on research from the labs of Drs. David Liu and Alan Saghetelian following their discovery of non-active site inhibitors that selectively reprogram the activity of Insulin Degrading Enzyme (IDE). Their groundbreaking work led to the development of Exo’s ExoSight platform and enabled us to build a foundational database of novel exosite targets and a rapidly advancing portfolio innovative drug candidates.
Exo has assembled a team of seasoned industry leaders, world class investors and expert advisors.